Cargando…

AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction

Nocturnal penile tumescence (NPT) was firstly described by Halverson in 1940’s and eventually applied in erectile function examination in 1970 for the first time. However, synchronous assessment of nocturnal penile tumescence and rigidity (NPTR) was not available before 1985 until the invention of R...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhang, Xiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186725/
http://dx.doi.org/10.21037/tau.2018.AB039
_version_ 1783362889550135296
author Zhang, Xiansheng
author_facet Zhang, Xiansheng
author_sort Zhang, Xiansheng
collection PubMed
description Nocturnal penile tumescence (NPT) was firstly described by Halverson in 1940’s and eventually applied in erectile function examination in 1970 for the first time. However, synchronous assessment of nocturnal penile tumescence and rigidity (NPTR) was not available before 1985 until the invention of RigiScan Plus. Unlike other instruments, RigiScan Plus is still the only one which is able to evaluate NPTR so far. Clinicians can distinguish psychogenic from organic erectile dysfunction (ED) employing RigiScan Plus NPTR inspection. Comparing with the international index of erectile function questionnaire (IIEF) scores, RigiScan Plus assessment provides an objective and intuitive way to judge erectile function. Therefore, it has been widely accepted as a gold standard of ED diagnosis listed in a series guideline of urology and andrology societies, including European Association of Urology (EAU), Chinese Urological Association (CUA), American Urology Association (AUA) and Canadian Urological Association (CAU). Besides NPTR evaluation, RigiScan Plus can be also applied in audio visual sexual stimuli (AVSS), which facilitates daily simple examination for those cases visiting outpatient clinics. Nowadays, RigiScan Plus assessment provides reliable and accurate profiles in various clinical and judicial applications, including ED treatment suggestion, medication or physical therapy evaluation, prediction of prognosis and curative effect in traumatic ED, evaluation of pelvic surgery influence on erectile function, as well as legal and medical authentication.
format Online
Article
Text
id pubmed-6186725
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-61867252018-10-26 AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction Zhang, Xiansheng Transl Androl Urol Podium Lecture Nocturnal penile tumescence (NPT) was firstly described by Halverson in 1940’s and eventually applied in erectile function examination in 1970 for the first time. However, synchronous assessment of nocturnal penile tumescence and rigidity (NPTR) was not available before 1985 until the invention of RigiScan Plus. Unlike other instruments, RigiScan Plus is still the only one which is able to evaluate NPTR so far. Clinicians can distinguish psychogenic from organic erectile dysfunction (ED) employing RigiScan Plus NPTR inspection. Comparing with the international index of erectile function questionnaire (IIEF) scores, RigiScan Plus assessment provides an objective and intuitive way to judge erectile function. Therefore, it has been widely accepted as a gold standard of ED diagnosis listed in a series guideline of urology and andrology societies, including European Association of Urology (EAU), Chinese Urological Association (CUA), American Urology Association (AUA) and Canadian Urological Association (CAU). Besides NPTR evaluation, RigiScan Plus can be also applied in audio visual sexual stimuli (AVSS), which facilitates daily simple examination for those cases visiting outpatient clinics. Nowadays, RigiScan Plus assessment provides reliable and accurate profiles in various clinical and judicial applications, including ED treatment suggestion, medication or physical therapy evaluation, prediction of prognosis and curative effect in traumatic ED, evaluation of pelvic surgery influence on erectile function, as well as legal and medical authentication. AME Publishing Company 2018-09 /pmc/articles/PMC6186725/ http://dx.doi.org/10.21037/tau.2018.AB039 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Podium Lecture
Zhang, Xiansheng
AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title_full AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title_fullStr AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title_full_unstemmed AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title_short AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
title_sort ab039. the application of rigiscan in the diagnosis and treatment of erectile dysfunction
topic Podium Lecture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186725/
http://dx.doi.org/10.21037/tau.2018.AB039
work_keys_str_mv AT zhangxiansheng ab039theapplicationofrigiscaninthediagnosisandtreatmentoferectiledysfunction